Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand (TRAIL)
Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand (TRAIL)
复制标题
DOI：
10.1007/978-1-4471-6458-6_8
复制
发表时间：
2014-01-01
期刊：
影响因子：
--
通讯作者：
Fulda, Simone
中科院分区：
文献类型：
--
作者：
Fulda, Simone
利用死亡受体进行癌症治疗的概念非常有吸引力，因为这些细胞表面受体与细胞内细胞死亡机制有直接联系。在死亡受体超家族中，肿瘤坏死因子相关凋亡诱导配体（TRAIL）受体/配体系统特别令人感兴趣。TRAIL受体激动剂最近已进入用于治疗人类癌症的临床评价阶段。进一步深入了解TRAIL信号的调控机制将有助于更好地理解人类癌症的TRAIL敏感性与耐药性的决定因素。
The concept to exploit death receptors for cancer therapy is very attractive, since these cell surface receptors have a direct connection to the intracellular cell death machinery. Among the death receptor superfamily, the tumornecrosis- factor-related apoptosis-inducing ligand (TRAIL) receptor/ligand system is of special interest. TRAIL receptor agonists have recently entered the stage of clinical evaluation for the treatment of human cancers. Further insights into the regulatory mechanisms of TRAIL signaling will help to better understand the determinants of TRAIL sensitivity versus resistance of human cancers.